Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.

①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.

cls.cnSep 11 03:59 ET

Tsubota Lab has signed an exclusive implementation license agreement with shenyang xingqi pharmaceutical.

On the 5th, Tobita Lab <4890> announced that they have signed a patent license agreement with China's ophthalmology drug manufacturer Shenyang Xingqi Pharmaceutical (hereinafter referred to as Xingqi) to grant exclusive rights to certain patents in specific regions.

Fisco JapanSep 11 02:21 ET

Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference

① At the results meeting, Yang Liang, director of Lizhu Group, responded to issues such as the year-on-year decline in the company's revenue and financial data in various segments; ② Tang Yanggang, president of the company, said that the overall market size of tocilizumab injections in China is small.

cls.cnSep 10 07:50 ET

Cisen Pharmaceutical's sales volume of the winning varieties in the centralized procurement has increased significantly. It is predicted that the sales of the large infusion sector will trend towards stability in the second half of the year. | Live from t

①At the earnings conference, the director of Cisen Pharmaceutical, Xu Xinbing, explained the gross margin and revenue decline of the company in the first half of the year. ②Xu Xinbing said that the company's sales volume of four varieties that were awarded in the eighth batch of centralized procurement showed a significant year-on-year increase. ③Du Zhenxin, the chairman of the company, introduced the company's development of generic drugs and innovative drugs.

cls.cnSep 9 05:55 ET

Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.

①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.

cls.cnSep 4 09:29 ET

Decline in revenue from the sales sector, zhejiang shapuaisi pharmaceutical incurs losses in H1 | interpretations

①Affected by factors such as the decline in sales of eye drops and cephalosporin drugs, the H1 performance of Zhejiang Shapuaisi pharmaceutical has declined significantly, resulting in a year-on-year loss. ②The company's main business, the commodity sales sector, saw a year-on-year decrease in revenue of more than 40%.

cls.cnAug 30 09:39 ET